acquired
Stage
1
Investors
About
Developed automated molecular diagnostic instruments and reagent assays (sample-to-result PCR systems) for infectious disease and oncology testing. The company was acquired by QIAGEN in September 2020.
Explore NeuMoDx Molecular's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.